Click for best price
NonAlcoholic Steatohepatitis NASH Drugs Market Size, Share 2023
The global Non-Alcoholic Steatohepatitis (NASH) Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The USA market for Global Non-Alcoholic Steatohepatitis (NASH) Drugs market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The China market for Global Non-Alcoholic Steatohepatitis (NASH) Drugs market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Non-Alcoholic Steatohepatitis (NASH) Drugs market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
This report aims to provide a comprehensive presentation of the global market for Non-Alcoholic Steatohepatitis (NASH) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Alcoholic Steatohepatitis (NASH) Drugs. This report contains market size and forecasts of Non-Alcoholic Steatohepatitis (NASH) Drugs in global, including the following market information:
- Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global top five companies in 2022 (%)
This market is boosted by the growing prevalence of diabetes and obesity, and high investments for research and development, which leads to rising demand for NASH and others nonalcoholic fatty liver diseases (NAFLD) therapies in the market. As per the regional analysis, the well-established healthcare infrastructure with the high adoption rate of new technologies and increasing research activities, makes North America dominate this market.
We surveyed the Non-Alcoholic Steatohepatitis (NASH) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Percentages, by Type, 2022 (%)
- Vitamin E & Pioglitazone
- Obeticholic Acid (OCA)
- Elafibranor
- Selonsertib & Cenicriviroc
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Percentages, by Application, 2022 (%)
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Non-Alcoholic Steatohepatitis (NASH) Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Non-Alcoholic Steatohepatitis (NASH) Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- AstraZeneca
- Conatus Pharmaceuticals
- Enzo Biochem
- Galmed Pharmaceuticals
- Genfit
- Gilead
- Horizon Pharma
- Immuron
- Intercept Pharmaceuticals
- Novo Nordisk
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Alcoholic Steatohepatitis (NASH) Drugs, market overview.
Chapter 2: Global Non-Alcoholic Steatohepatitis (NASH) Drugs market size in revenue.
Chapter 3: Detailed analysis of Non-Alcoholic Steatohepatitis (NASH) Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Alcoholic Steatohepatitis (NASH) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Non-Alcoholic Steatohepatitis (NASH) Drugs Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
67 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Overall Market Size
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size: 2022 VS 2030
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players in Global Market
3.2 Top Global Non-Alcoholic Steatohepatitis (NASH) Drugs Companies Ranked by Revenue
3.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Companies
3.4 Top 3 and Top 5 Non-Alcoholic Steatohepatitis (NASH) Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-Alcoholic Steatohepatitis (NASH) Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Drugs Players in Global Market
3.6.1 List of Global Tier 1 Non-Alcoholic Steatohepatitis (NASH) Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Markets, 2022 & 2030
4.1.2 Vitamin E & Pioglitazone
4.1.3 Obeticholic Acid (OCA)
4.1.4 Elafibranor
4.1.5 Selonsertib & Cenicriviroc
4.2 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue & Forecasts
4.2.1 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2018-2023
4.2.2 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2024-2030
4.2.3 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2022 & 2030
5.1.2 Hospital Pharmacy
5.1.3 Online Provider
5.1.4 Retail Pharmacy
5.2 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue & Forecasts
5.2.1 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2018-2023
5.2.2 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2024-2030
5.2.3 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2022 & 2030
6.2 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue & Forecasts
6.2.1 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2018-2023
6.2.2 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2024-2030
6.2.3 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2018-2030
6.3.2 US Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.3.3 Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.3.4 Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2018-2030
6.4.2 Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.4.3 France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.4.4 U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.4.5 Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.4.6 Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.4.7 Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.4.8 Benelux Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2018-2030
6.5.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.5.3 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.5.4 South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.5.5 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.5.6 India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2018-2030
6.6.2 Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.6.3 Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2018-2030
6.7.2 Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.7.3 Israel Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.7.4 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
6.7.5 UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, 2018-2030
7 Non-Alcoholic Steatohepatitis (NASH) Drugs Companies Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.1.4 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2018-2023)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Conatus Pharmaceuticals
7.2.1 Conatus Pharmaceuticals Company Summary
7.2.2 Conatus Pharmaceuticals Business Overview
7.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.2.4 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2018-2023)
7.2.5 Conatus Pharmaceuticals Key News & Latest Developments
7.3 Enzo Biochem
7.3.1 Enzo Biochem Company Summary
7.3.2 Enzo Biochem Business Overview
7.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.3.4 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2018-2023)
7.3.5 Enzo Biochem Key News & Latest Developments
7.4 Galmed Pharmaceuticals
7.4.1 Galmed Pharmaceuticals Company Summary
7.4.2 Galmed Pharmaceuticals Business Overview
7.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.4.4 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2018-2023)
7.4.5 Galmed Pharmaceuticals Key News & Latest Developments
7.5 Genfit
7.5.1 Genfit Company Summary
7.5.2 Genfit Business Overview
7.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.5.4 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2018-2023)
7.5.5 Genfit Key News & Latest Developments
7.6 Gilead
7.6.1 Gilead Company Summary
7.6.2 Gilead Business Overview
7.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.6.4 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2018-2023)
7.6.5 Gilead Key News & Latest Developments
7.7 Horizon Pharma
7.7.1 Horizon Pharma Company Summary
7.7.2 Horizon Pharma Business Overview
7.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.7.4 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2018-2023)
7.7.5 Horizon Pharma Key News & Latest Developments
7.8 Immuron
7.8.1 Immuron Company Summary
7.8.2 Immuron Business Overview
7.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.8.4 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2018-2023)
7.8.5 Immuron Key News & Latest Developments
7.9 Intercept Pharmaceuticals
7.9.1 Intercept Pharmaceuticals Company Summary
7.9.2 Intercept Pharmaceuticals Business Overview
7.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.9.4 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2018-2023)
7.9.5 Intercept Pharmaceuticals Key News & Latest Developments
7.10 Novo Nordisk
7.10.1 Novo Nordisk Company Summary
7.10.2 Novo Nordisk Business Overview
7.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Major Product Offerings
7.10.4 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global Market (2018-2023)
7.10.5 Novo Nordisk Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Opportunities & Trends in Global Market
Table 2. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers in Global Market
Table 3. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints in Global Market
Table 4. Key Players of Non-Alcoholic Steatohepatitis (NASH) Drugs in Global Market
Table 5. Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-Alcoholic Steatohepatitis (NASH) Drugs Product Type
Table 9. List of Global Tier 1 Non-Alcoholic Steatohepatitis (NASH) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2024-2030
Table 30. AstraZeneca Company Summary
Table 31. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 32. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. AstraZeneca Key News & Latest Developments
Table 34. Conatus Pharmaceuticals Company Summary
Table 35. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 36. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Conatus Pharmaceuticals Key News & Latest Developments
Table 38. Enzo Biochem Company Summary
Table 39. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 40. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Enzo Biochem Key News & Latest Developments
Table 42. Galmed Pharmaceuticals Company Summary
Table 43. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 44. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Galmed Pharmaceuticals Key News & Latest Developments
Table 46. Genfit Company Summary
Table 47. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 48. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Genfit Key News & Latest Developments
Table 50. Gilead Company Summary
Table 51. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 52. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Gilead Key News & Latest Developments
Table 54. Horizon Pharma Company Summary
Table 55. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 56. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Horizon Pharma Key News & Latest Developments
Table 58. Immuron Company Summary
Table 59. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 60. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. Immuron Key News & Latest Developments
Table 62. Intercept Pharmaceuticals Company Summary
Table 63. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 64. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. Intercept Pharmaceuticals Key News & Latest Developments
Table 66. Novo Nordisk Company Summary
Table 67. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product Offerings
Table 68. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Novo Nordisk Key News & Latest Developments
List of Figures
Figure 1. Non-Alcoholic Steatohepatitis (NASH) Drugs Segment by Type in 2022
Figure 2. Non-Alcoholic Steatohepatitis (NASH) Drugs Segment by Application in 2022
Figure 3. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2022
Figure 8. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2018-2030
Figure 9. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2018-2030
Figure 10. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2018-2030
Figure 12. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2018-2030
Figure 14. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2018-2030
Figure 15. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2018-2030
Figure 16. US Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2018-2030
Figure 20. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 21. France Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2018-2030
Figure 28. China Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 32. India Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2018-2030
Figure 34. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share, 2018-2030
Figure 37. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, (US$, Mn), 2018-2030
Figure 41. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
